Drug Approval | March 07, 2022
NATCO launches first generic version of Revlimid in the US
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
Novel technology combines ACUVUE daily disposable contact lenses with an established antihistamine in FDA- first in its new category
The guidance also urges companies to act quickly to initiate a recall when public health is at risk and to do so prior to completing an investigation into the cause of the problem
Covaxin is not approved in the USA for any age group
Ten new Ayush hospitals and one Ayurvedic college will be set up in Nagaland and Mizoram
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
The product will be manufactured at Lupin’s facility in Pithampur, India
Company expects strong organic growth in sales, EBITDA in 2022
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
Subscribe To Our Newsletter & Stay Updated
